Gene test could personalize heart drug treatment
NCT ID NCT07408427
First seen Feb 16, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study looks at why the heart drug mavacamten works better for some people with hypertrophic cardiomyopathy (a condition where the heart muscle thickens). Researchers will check if a person's specific gene causing HCM and their natural ability to process medications (via the CYP2C19 gene) affect the drug's performance. About 140 adults with obstructive HCM will participate to help tailor future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Manchester Centre for Genomic Medicine (MCGM)
Multiple Locations, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.